Melatonin

Does it have utility in the treatment of haematological neoplasms?

Tian Li, Zhi Yang, Shuai Jiang, Wencheng Di, Zhiqiang Ma, Wei Hu, Fulin Chen, Russel J Reiter, Yang Yang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Melatonin, discovered in 1958 in the bovine pineal tissue, is an indoleamine that modulates circadian rhythms and has a wide variety of other functions. Haematological neoplasms are the leading cause of death in children and adolescents throughout the world. Research has demonstrated that melatonin is a low-toxicity protective molecule against experimental haematological neoplasms, but the mechanisms remain poorly defined. Here, we provide an introduction to haematological neoplasms and melatonin, especially as they relate to the actions of melatonin on haematological carcinogenesis. Secondly, we summarize what is known about the mechanisms of action of melatonin in the haematological system, including its pro-apoptotic, pro-oxidative, anti-proliferative and immunomodulatory actions. Thirdly, we discuss the advantages of melatonin in combination with other drugs against haematological malignancy, as well as its other benefits on the haematological system. Finally, we summarize the findings that are contrary to the suppressive effects of melatonin on cancers of haematological origin. We hope that this information will be helpful in the design of studies related to the therapeutic efficacy of melatonin in haematological neoplasms.

Original languageEnglish (US)
JournalBritish Journal of Pharmacology
DOIs
StateAccepted/In press - 2017

Fingerprint

Hematologic Neoplasms
Melatonin
Therapeutics
Experimental Neoplasms
Circadian Rhythm
Cause of Death
Carcinogenesis
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Melatonin : Does it have utility in the treatment of haematological neoplasms? / Li, Tian; Yang, Zhi; Jiang, Shuai; Di, Wencheng; Ma, Zhiqiang; Hu, Wei; Chen, Fulin; Reiter, Russel J; Yang, Yang.

In: British Journal of Pharmacology, 2017.

Research output: Contribution to journalArticle

Li, Tian ; Yang, Zhi ; Jiang, Shuai ; Di, Wencheng ; Ma, Zhiqiang ; Hu, Wei ; Chen, Fulin ; Reiter, Russel J ; Yang, Yang. / Melatonin : Does it have utility in the treatment of haematological neoplasms?. In: British Journal of Pharmacology. 2017.
@article{ad10e6a59a744f07802c15dd4f3bc74e,
title = "Melatonin: Does it have utility in the treatment of haematological neoplasms?",
abstract = "Melatonin, discovered in 1958 in the bovine pineal tissue, is an indoleamine that modulates circadian rhythms and has a wide variety of other functions. Haematological neoplasms are the leading cause of death in children and adolescents throughout the world. Research has demonstrated that melatonin is a low-toxicity protective molecule against experimental haematological neoplasms, but the mechanisms remain poorly defined. Here, we provide an introduction to haematological neoplasms and melatonin, especially as they relate to the actions of melatonin on haematological carcinogenesis. Secondly, we summarize what is known about the mechanisms of action of melatonin in the haematological system, including its pro-apoptotic, pro-oxidative, anti-proliferative and immunomodulatory actions. Thirdly, we discuss the advantages of melatonin in combination with other drugs against haematological malignancy, as well as its other benefits on the haematological system. Finally, we summarize the findings that are contrary to the suppressive effects of melatonin on cancers of haematological origin. We hope that this information will be helpful in the design of studies related to the therapeutic efficacy of melatonin in haematological neoplasms.",
author = "Tian Li and Zhi Yang and Shuai Jiang and Wencheng Di and Zhiqiang Ma and Wei Hu and Fulin Chen and Reiter, {Russel J} and Yang Yang",
year = "2017",
doi = "10.1111/bph.13966",
language = "English (US)",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Melatonin

T2 - Does it have utility in the treatment of haematological neoplasms?

AU - Li, Tian

AU - Yang, Zhi

AU - Jiang, Shuai

AU - Di, Wencheng

AU - Ma, Zhiqiang

AU - Hu, Wei

AU - Chen, Fulin

AU - Reiter, Russel J

AU - Yang, Yang

PY - 2017

Y1 - 2017

N2 - Melatonin, discovered in 1958 in the bovine pineal tissue, is an indoleamine that modulates circadian rhythms and has a wide variety of other functions. Haematological neoplasms are the leading cause of death in children and adolescents throughout the world. Research has demonstrated that melatonin is a low-toxicity protective molecule against experimental haematological neoplasms, but the mechanisms remain poorly defined. Here, we provide an introduction to haematological neoplasms and melatonin, especially as they relate to the actions of melatonin on haematological carcinogenesis. Secondly, we summarize what is known about the mechanisms of action of melatonin in the haematological system, including its pro-apoptotic, pro-oxidative, anti-proliferative and immunomodulatory actions. Thirdly, we discuss the advantages of melatonin in combination with other drugs against haematological malignancy, as well as its other benefits on the haematological system. Finally, we summarize the findings that are contrary to the suppressive effects of melatonin on cancers of haematological origin. We hope that this information will be helpful in the design of studies related to the therapeutic efficacy of melatonin in haematological neoplasms.

AB - Melatonin, discovered in 1958 in the bovine pineal tissue, is an indoleamine that modulates circadian rhythms and has a wide variety of other functions. Haematological neoplasms are the leading cause of death in children and adolescents throughout the world. Research has demonstrated that melatonin is a low-toxicity protective molecule against experimental haematological neoplasms, but the mechanisms remain poorly defined. Here, we provide an introduction to haematological neoplasms and melatonin, especially as they relate to the actions of melatonin on haematological carcinogenesis. Secondly, we summarize what is known about the mechanisms of action of melatonin in the haematological system, including its pro-apoptotic, pro-oxidative, anti-proliferative and immunomodulatory actions. Thirdly, we discuss the advantages of melatonin in combination with other drugs against haematological malignancy, as well as its other benefits on the haematological system. Finally, we summarize the findings that are contrary to the suppressive effects of melatonin on cancers of haematological origin. We hope that this information will be helpful in the design of studies related to the therapeutic efficacy of melatonin in haematological neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=85029067635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029067635&partnerID=8YFLogxK

U2 - 10.1111/bph.13966

DO - 10.1111/bph.13966

M3 - Article

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -